U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H18N3O10.3Na.Zn
Molecular Weight 522.685
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENTETATE ZINC TRISODIUM

SMILES

[Na+].[Na+].[Na+].[Zn++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O

InChI

InChIKey=HVASDHJNLYRZEA-UHFFFAOYSA-I
InChI=1S/C14H23N3O10.3Na.Zn/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;;;;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);;;;/q;3*+1;+2/p-5

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C14H18N3O10
Molecular Weight 388.3068
Charge -5
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.federalregister.gov/articles/2011/08/19/2011-21227/determination-that-pentetate-calcium-trisodium-trisodium-calcium-diethylenetriaminepentaacetate

Pentetate calcium trisodium is also known as trisodium calcium diethylenetriaminepentaacetate and is commonly referred to as Ca-DTPA is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. It is a white, water-soluble solid. It has a molecular formula of Na3CaC14H18N3O10 and a molecular weight of 497.4 Daltons. Ca-DTPA is supplied as a clear, colorless, hyperosmolar (1260 mOsmol/kg) solution in a colorless ampoule containing 5 mL. The ampoule contents are sterile, non-pyrogenic and suitable for intravenous administration. Each mL of solution contains the equivalent of 200 mg pentetate calcium trisodium (obtained from 158.17 mg pentetic acid, 40.24 mg calcium carbonate and NaOH) in water for injection, USP. The pH of the solution is adjusted with NaOH and is between 7.3 - 8.3. Ca-DTPA forms stable chelates with metal ions by exchanging calcium for a metal of greater binding capacity. The radioactive chelates are then excreted by glomerular filtration into the urine. In animal studies, Ca-DTPA forms less stable chelates with uranium and neptunium in vivo resulting in the deposition of these elements in tissues including the bone. The Food and Drug Administration (FDA) has determined that PENTETATE CALCIUM TRISODIUM (trisodium calcium diethylenetriaminepentaacetate (Ca-DTPA)) solution for intravenous or inhalation administration, equivalent to (EQ) 1 gram (g) base/5 milliliters (mL) (EQ 200 milligrams (mg) base/mL) was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for PENTETATE CALCIUM TRISODIUM (Ca-DTPA) solution for intravenous or inhalation administration (EQ 1 g base/5 mL (EQ 200 mg base/mL)), if all other legal and regulatory requirements are met. Ca-DTPA treatments are not expected to be effective for uranium and neptunium. Radioactive iodine is not bound by DTPA

Originator

Curator's Comment: Akorn licensed Ca-DTPA and Zn-DTPA from Hameln Pharmaceuticals gmbh in October 2004.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Inactive ingredient
DermaKlear Akne Treatment with Sulfur

Approved Use

Uses for the treatment of acne. Dries acne blemishes and allows skin to heal. Helps prevent new acne blemishes from forming.

Launch Date

1940
Diagnostic
PENTETATE CALCIUM TRISODIUM

Approved Use

Ca-DTPA is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.

Launch Date

2004
Palliative
PENTETATE ZINC TRISODIUM

Approved Use

Pentetate zinc trisodium injection is a radiomitigation chelator indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.6 nM
29.4 μmol/kg single, intravenous
dose: 29.4 μmol/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTETIC ACID plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.007 nM × h
29.4 μmol/kg single, intravenous
dose: 29.4 μmol/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTETIC ACID plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.53 h
29.4 μmol/kg single, intravenous
dose: 29.4 μmol/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PENTETIC ACID plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 g 1 times / day multiple, subcutaneous (starting)
Dose: 0.5 g, 1 times / day
Route: subcutaneous
Route: multiple
Dose: 0.5 g, 1 times / day
Co-administed with::
Zinc sulphate(200 mg two to five times daily)
Sources:
unhealthy, 5-20 years)
n = 5
Health Status: unhealthy
Condition: homozygous beta thalassaemia
Age Group: 5-20 years)
Sex: M+F
Population Size: 5
Sources:
4 g 1 times / day multiple, intramuscular
Overdose
Dose: 4 g, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 g, 1 times / day
Sources:
unhealthy
Other AEs: Hemochromatosis...
Other AEs:
Hemochromatosis (grade 5, 3 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hemochromatosis grade 5, 3 patients
4 g 1 times / day multiple, intramuscular
Overdose
Dose: 4 g, 1 times / day
Route: intramuscular
Route: multiple
Dose: 4 g, 1 times / day
Sources:
unhealthy
PubMed

PubMed

TitleDatePubMed
Chelation of zinc amplifies induction of growth hormone mRNA levels in cultured rat pituitary tumor cells.
2000 Feb
Blood-pool scintigraphic diagnosis of fractured lumbar vertebral hemangioma.
2001 Apr
Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results.
2001 Apr
Bilaminar pattern of tibial condyle cartilage layer on the fat-suppressed 3D gradient echo images: artifact or structural and biochemical difference in composition of cartilage?
2001 Feb
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.
2001 Feb
Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage.
2001 Feb
Early retardation of 99mTc-DTPA radioaerosol transalveolar clearance in irradiated canine lung.
2001 Feb
[The scintigraphy of somatostatin receptors in the carcinoid tumor].
2001 Feb
Glycoxidation and lipid peroxidation of low-density lipoprotein can synergistically enhance atherogenesis.
2001 Feb 1
Biokinetics of 111In-DTPA-D-Phe(1)-octreotide in nude mice transplanted with a human carcinoid tumor.
2001 Jan
Chelating agents.
2001 Jan-Feb
Somatostatin receptor imaging: current status and future perspectives.
2001 Jul
Early responses to nonconjugated polyribosylribitol phosphate challenge as evidence of immune memory after combined diphtheria-tetanus-pertussis-polio-Haemophilus influenzae type b primary vaccination.
2001 Jun
Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction.
2001 Mar
Synthesis, characterization, and relaxivity of two linear Gd(DTPA)-polymer conjugates.
2001 Mar-Apr
Rapid imaging of human melanoma xenografts using an scFv fragment of the human monoclonal antibody H11 labelled with 111In.
2001 May
Negatively charged polymers protect antinuclear antibody against inactivation by acylating agents.
2001 May 15
Final report on the safety assessment of pentasodium pentetate and pentetic acid as used in cosmetics.
2008
Patents

Sample Use Guides

Rats: The acute oral LD(50) of Pentasodium Pentetate in rats was > 5 g/kg. The acute dermal LD(50) of Pentapotassium Pentetate using rats was reported to be > 2 g/kg. The intraperitonal LD(50) of Pentetic Acid was reported to be 585 mg/kg.
Route of Administration: Other
Approximately 0.1 ml of solution of Ca-DTPA (pentetate calcium trisodium) was added to the test cultures (human lymphocytes) at 3 different concentrations: 0.77, 0.077, and 0.0077 mg/ml, resulting in a final concentration in the culture medium of 13.51, 1.351, and 0.135 ug/ml, respectively.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:40:15 GMT 2023
Edited
by admin
on Fri Dec 15 15:40:15 GMT 2023
Record UNII
NXU65IC8PG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENTETATE ZINC TRISODIUM
HSDB   ORANGE BOOK   VANDF   WHO-DD  
Common Name English
TRISODIUM (N,N-BIS(2-(BIS(CARBOXYLATOMETHYL)AMINO)ETHYL)GLYCINATO(5-))ZINCATE(3-)
Common Name English
PENTETATE ZINC TRISODIUM [VANDF]
Common Name English
TRISODIUM ZINC DTPA
Common Name English
PENTETATE ZINC TRISODIUM [HSDB]
Common Name English
DIETHYLENETRIAMINE PENTACETIC ACID TRISODIUM ZINC SALT
Common Name English
PENTETATE ZINC TRISODIUM [ORANGE BOOK]
Common Name English
DIETHYLENETRIAMINEPENTAACETIC ACID, ZINC TRISODIUM SALT
Common Name English
ZINC TRISODIUM PENTETATE
MART.  
Common Name English
TRISODIUM ZINC DIETHYLENETRIAMINEPENTAACETATE
Common Name English
ZINCATE(3-), (N,N-BIS(2-(BIS(CARBOXYMETHYL)AMINO)ETHYL)GLYCINATO(5-))-, TRISODIUM
Common Name English
Pentetate zinc trisodium [WHO-DD]
Common Name English
ZINC TRISODIUM PENTETATE [MART.]
Common Name English
PENTETATE ZINC TRISODIUM [JAN]
Common Name English
KELAZIN
Brand Name English
ZINC-DTPA
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C62357
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
FDA ORPHAN DRUG 181003
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
Code System Code Type Description
EVMPD
SUB121183
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
CAS
11082-38-5
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
CAS
125833-02-5
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
ALTERNATIVE
PUBCHEM
164209
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
NCI_THESAURUS
C77835
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
DRUG CENTRAL
4754
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
HSDB
7432
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
ChEMBL
CHEMBL780
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
FDA UNII
NXU65IC8PG
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
EPA CompTox
DTXSID80154954
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
DRUG BANK
DBSALT002669
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
RXCUI
11431
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
ALTERNATIVE
SMS_ID
100000144541
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
DAILYMED
NXU65IC8PG
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
RXCUI
408077
Created by admin on Fri Dec 15 15:40:15 GMT 2023 , Edited by admin on Fri Dec 15 15:40:15 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY
ACTIVE MOIETY